Consistent with this, a recent report demonstrated that combined treatment with MEK and JAK2 inhibitors significantly prolonged survival in an N-RasG12D-induced CMML (chronic myelomonocytic leukemia) mouse model (Kong et al., 2014). The gene discussed is JAK2; the disease is chronic myelomonocytic leukemia.